Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Experimental attempt to produce mRNA transfected dendritic cells derived from enriched CD34+ blood progenitor cells

100%
Lazarova P., Kvalheim G., Gercheva L., Metodiev K.
Open Medicine
|
2008
|
vol. 3
|
issue 1
21-28
EN
It Peripheral blood progenitor enriched CD34+ cells (PBPC) are rather often used as stem cell background in cancer patients following high dose therapy. Keeping in mind that precursor dendritic cells (DCs) originate from haematopoietic progenitor cells, purified CD34+ cells might also serve as starting cells for ex-vivo production of DC. The aim of the present study is to develop a clinical grade procedure for ex-vivo production of DC derived from enriched CD34+ cells. Various concentrations of CD34+ cells were grown in gas-permeable Teflon bags with different serum-free and serum-containing media supplemented with GM-CSF, IL-4, TNF-a, SCF, Flt-3L and INF-a. Serum-free CellGroSCGM medium for 7 days followed by CellGroDC medium in 7 days gave equal results as serum-containing medium. Following incubation, the cultured cells containing immature DCs were concentrated and transfected with tumour mRNA from human prostate cancer cell lines employing a highly efficient electroporation procedure. Thawed transfected DCs were able to elicit primary T-cell responses in vitro against antigens encoded by the prostate cancer mRNA as shown by ELISPOT assay using mock-transfected DCs as control. The results of our study show that frozen enriched CD34+ cells can be an alternative and efficient source for production of DCs for therapeutic purpose.
2
Content available remote

Cytostatic therapy and blood antioxidants/prooxidants balance in acute myeloblastic leukemia patients

88%
Gerova D., Gerov V., Yankova T., Gercheva L., Ivanova D.
Open Medicine
|
2006
|
vol. 1
|
issue 1
35-45
EN
To analyze the effects of conventional polychemotherapy of acute myeloblastic leukemia (AML) patients on the prooxidants/antioxidants balance in plasma total antioxidant status (TAS) and a single plasma antioxidant - uric acid (UA) were measured. Lipid peroxidation was assessed by malonedialdehyde (MDA) content. Total serum iron was monitored as a potential source of nontransferrin-bound iron with a role in initiation of oxidative burst. A group of patients in the acute phase of AML (group A) and a group of patients in complete remission of AML (group B) were studied. A strong correlation between UA values and TAS (r = 0.8 for group A, r = 0.9 for group B) was revealed in the course of the treatment. Strong negative correlation (r = −0.9) between TAS and MDA was shown for both groups. Total iron significantly increased in the course of chemotherapy. We have established that polychemotherapy leads to the consumption of antioxidants and increased lipid peroxidation in AML patients. An appropriate supplementation with antioxidants at the end of the polychemotherapy treatment could be considered.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.